ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

Publication
Article
Oncology Nurse EditionONCOLOGY Nurse Edition Vol 22 No 11
Volume 22
Issue 11

October 2008, Vol 22 No 11

Main Articles

Psychological Challenges After Cancer: A Guide for Clinical Practice Reviewed in:

The Recklitis et al Article Reviewed

LATE EFFECTS CLINIC: Post-Trauma Symptoms in Cancer Survivors

Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell Transplant Reviewed in:

The Barton-Burke et al Article Reviewed

DRUG ESSENTIALS: Small Molecule Multitargeted TKI Therapy

PATIENT INFORMATION: Fatigue in People with Cancer

Articles in this issue
The Recklitis et al Article Reviewed
A Challenge of Survivorship-Healing the Mind and Spirit
ONCOLOGY Nurse Edition October 2008, Vol 22 No 11
Addressing Psychological Challenges After Cancer: A Guide for Clinical Practice
Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell
Post-Trauma Symptoms in Cancer Survivors
Small Molecule Multitargeted TKI Therapy
Commentary (Ezzone)-Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell
La fatiga en personas con cáncer
Fatigue in People With Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
Related Content
A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
July 1st 2025
Article

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

ONCOLOGY Staff
July 1st 2025
Article

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

Radhika Appaya;Sarah Sammons, MD;Priyanka Sharma, MD;Yara Abdou;VK Gadi, MD, PhD;Taavy A. Miller;Spencer S. Langerman;Dominick Latremouille-Viau;Annie Guerin;Carmine Rossi;Emily McGovern;Gary Sopher;Vamsi Bollu;Natalia Bolotova;Şerban R. Iorga;Liz Santarsiero;Susan Dent, MD
June 30th 2025
Article

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Gina Mauro
June 30th 2025
Article

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.